Funding round for InhalPlus
Biomarker platform for protein aggregates · Hannover, Germanyfunding round withNBank Capital
NBank Capital invests €12m in InhalPlus from Hanover. The company develops the biomarker platform SeRAS for detecting pathological protein aggregates.
- Lead investor
- NBank Capital
- Target
- InhalPlus, Hannover
- Type
- Funding round
- Sector
- Healthcare & Medtech
- Country
- Germany
- First reported
- 22/10/2026
- Source
- transkript.de
Deal-Radar no. 43-075 · publicly reported, without guarantee · SourcingClub was not involved in this transaction. Report an error · Method
Transactions by NBank Capital
So far this is the only transaction by NBank Capital published in the Deal-Radar. New deals are added every Monday.
Venture and growth in Week 43/2026
All deals in October 2026Every Monday, all deals of the previous week, with source.
Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 26 October 2026.